Josh Jennings

Internationally, any quantification of how Volt is impacting share recapture in the ablation catheter segment?

the focus for your team, Robert, has been to kind of look at inorganic ads for the devices and diagnostics franchise

was hoping you could just help us better understand the drivers of the double-digit ablation catheter growth

how does Abbott view the market? And how do you see the franchise taking share and what will drive that

what Abbott Laboratories is doing individually or plans to do along with conjunction with AdvaMed

I was hoping you may just help us think through just the margin expansion opportunities in EPD, Nutrition and Diagnostics

the potential for the portfolio to drive an acceleration in organic revenue growth back into the mid-single-digit range

can that help drive price premiums and pricing be a tailwind in fiscal 2026 and into the out years

with the deceleration in high-margin products, U.S. EP franchise and WATCHMAN franchise, there may be incremental pressure there

wanted to hear about your confidence level in hitting your LRP targets through '28, specifically the 10%-plus organic

I am hoping to just get a state of affairs on capacity within the electrophysiology sector provider capacity

get your views and maybe weigh too early with the new administration issuing some policy decisions

does the patch that you just got approved, the new adhesive technology, maybe improve the percentage of sensors that get out to fifteen days

any updates on the G8 platform and whether or not ketone sensing has kind of moved up the priority list

where do you stand today? How much more work is left? Or do you feel like that channel has been stabilized and the DME partnerships are back to where they started at the end of 2023

Can you just talk about the strategy on a go-forward basis? I mean is it going to continue to be a mix

Just in the U.S., it sounds like that the slowdown may have been driven by just patients and physicians waiting for next-generation CGM and Instinct

get an update on the international opportunity, just where the business stands. Should we be thinking or could we be seeing some coverage and announcements in different countries?

what inning are we in, in this ASC infrastructure build-out in the U.S.? And two, can you just help us think about which businesses

Should we consider this kind of initial thrust into in the peripheral vascular kind of opening the door to other high-growth cardiovascular sectors

Should we be thinking that S.E.T. and Joints are performing kind of relatively similar in those two channels